Piezo Motion and Precise Motion unite to expand control and automation technologies
Piezo Motion’s innovative precision motors expand Precise Motion’s product offering and boost market demand from OEM manufacturers.
NEW YORK (Nov. 15, 2021) –– Piezo Motion, a Brain Scientific (OTCQB:BRSF) company, and Precise Motion & Control Inc. together announce a distribution partnership. Piezo Motion is a developer and leading manufacturer of precision motor technology. Precise Motion & Control, based in Tampa, Florida, specializes in motion control and industrial automation solutions. Through this partnership, Precise Motion will expand its product line to offer unique piezoelectric motors to its customers.
Piezo Motion’s unique technology meets Precise Motion’s needs for a compact design along with cost-effective automation. Piezo Motion’s multifaceted rotary and linear motors are built with technology that provides a stable, accurate motor that is designed specifically for OEMs that require ultimate speed, size, and accuracy.
“What was attractive to us was Piezo Motion offers advanced technology in a small, economical package,” explains Charlie White, president, and manager of Precise Motion. “Everything about their motors is intriguing. Generally, this type of precision mechanics has been too big and too expensive. We feel this will open a lot of doors in the markets we serve, especially the medical device market.”
Piezo Motion motors are used globally for a variety of applications. These include laboratory instruments, biomedicine, optics, semiconductors, nanotechnology industries, and industrial electronic and automotive systems, along with an expanding portfolio of products that combine performance with dramatically lower cost over conventional piezo solutions.
“Piezo Motion’s innovation continues to support the surge in market demand,” said Hassan Kotob, chairman and CEO of Brain Scientific. “The partnership with Precise Motion will deliver groundbreaking applications, especially for manufacturers that are looking for reliable motors to power devices that require performance and precision.”
About Piezo Motion
Piezo Motion (piezomotion.com), a Brain Scientific company, is a leader in precision motor technology with multimillion-dollar investments in research and development of affordable piezoelectric motors to meet, and exceed, the needs of today’s global markets. The company is committed to the development of innovative technology and motion products that enhance functionality in a multitude of applications. The company works with startups, OEMs, research institutions, and industrial companies from around the world, empowering the visionaries behind their products.
About Brain Scientific
Brain Scientific (brainscientific.com) is a medical technology company with multiple patents and FDA-cleared products. Brain Scientific is committed to developing next-gen solutions that advance the future of neurodiagnostic and OEM medical devices. Brain Scientific has two product lines covering neurology and precision motion. The NeuroCap and NeuroEEG are smart neurological diagnostic devices that simplify administration, shorten scan time and cut costs. The Piezo Motion product line consists of ultra-efficient compact precision motors that will drive the next generation of medical devices. To learn more about Brain Scientific’s corporate strategy, products, or investor relations, please visit brainscientific.com.
About Precise Motion
Precise Motion (precisemotion.com) is based in Tampa, Florida, and specializes in the application, sales, and support of motion control, automation, and process control products to service forward-looking companies in the industrial marketplace. The company’s objective is to aid in the selection and application of commercially available products from leading manufacturers to successfully solve unique automation applications.
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development, and commercialization of EEG products and services and piezo motor technology; (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items; (iii) the Company’s future financial performance; (iv) the successful integration of Piezo Motion with and into Brain Scientific; and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events, or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates, and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company’s inability to obtain additional financing; the significant length of time and resources associated with the development of products and related insufficient cash flows and resulting illiquidity; the Company’s inability to expand its business; significant government regulation of medical devices and the healthcare industry; lack of product diversification; volatility in the price of the Company’s raw materials; and the failure to implement the Company’s business plans or strategies, including as a result of the closing of the merger with Piezo Motion. Some of these and other factors are identified and described in more detail in the Company’s filings with the SEC. The Company does not undertake to update these forward-looking statements.